BRAF and melanoma: Vemurafenib was approved for the treatment of BRAF-mutated melanoma in 2012 after a phase III trial that reported a 0.37 hazard ratio for death in patients with BRAF mutations taking vemurafenib compared with dacarbazine, and a phase II trial showing 15.9 month median survival [8], [9].